stockrowBioXcel Therapeutics, Inc. (BTAIQ) vs China SXT Pharmaceuticals, Inc. (SXTC)
- BioXcel Therapeutics, Inc. BTAIQ 0.01 0.00%
- China SXT Pharmaceuticals, Inc. SXTC 2.92 −0.34%
BioXcel Therapeutics, Inc. and China SXT Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. BioXcel Therapeutics, Inc. is the larger, with a market value of $2.3M against $2.0M — 1.1× the size. BioXcel Therapeutics, Inc. grew revenue faster over the last twelve months: −14.5% against −54.0%. China SXT Pharmaceuticals, Inc. has the higher net margin (−255.2% vs −9,549.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, China SXT Pharmaceuticals, Inc. leads on 8 and BioXcel Therapeutics, Inc. on 6.
Valuation
| Metric | BTAIQ | SXTC | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| P/E | n/m | n/m | 20.55 |
| P/S | 0.41 | n/m | 2.08 |
| P/B | n/m | n/m | 1.79 |
| Price to free cash flow | n/m | n/m | 16.29 |
| EV/EBITDA | n/m | 2.66 | 12.22 |
| EV/Sales | 227.51 | (5.94) | 2.87 |
| Earnings yield | (37,900.00%) | (3,722.74%) | (15.94%) |
| Free cash flow yield | (16,806.60%) | 0.00% | 0.00% |
Profitability
| Metric | BTAIQ | SXTC | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 53.10% | 36.69% | 53.51% |
| Operating margin | (6,054.72%) | 0.00% | 0.00% |
| Net margin | (9,549.87%) | (255.16%) | (2.45%) |
| Free cash flow margin | (6,860.38%) | 0.00% | 0.00% |
| Return on equity | 63.52% | 0.00% | (0.80%) |
| Return on assets | (259.62%) | 0.00% | (1.67%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack